Pediatric Hospital Readmissions for Infants With Neonatal Opioid Withdrawal Syndrome, 2016-2019

Carly E Milliren1, Patrice Melvin2, Al Ozonoff3,4

  • 1Institutional Centers for Clinical and Translational Research carly.milliren@childrens.harvard.edu.

Hospital Pediatrics
|August 21, 2021
PubMed

Insights

Infants diagnosed with Neonatal Opioid Withdrawal Syndrome (NOWS) face a higher risk of hospital readmission within their first year. These readmissions are more frequent, longer, and costlier for NOWS infants compared to those without the condition.

Area of Science:

  • Neonatal care
  • Pediatric health outcomes
  • Public health

Background:

  • Neonatal Opioid Withdrawal Syndrome (NOWS) is linked to prolonged and expensive hospital stays.
  • Infants with NOWS have an increased risk of hospital readmission.
  • Understanding readmission patterns is crucial for improving infant care and resource allocation.

Purpose of the Study:

  • To compare readmission rates in the first year of life for infants with NOWS versus those without.
  • To identify factors influencing readmissions in NOWS infants.
  • To describe resource utilization during readmissions for NOWS infants.

Main Methods:

  • Analysis of singleton term infant data from the Pediatric Health Information System (2016-2019).
  • Identification of NOWS cases and comparison group using diagnosis codes and DRG coding.
  • Cox regression analysis to predict time to first readmission within one year.

Main Results:

  • The study included 155,885 infant discharges and 10,087 readmissions.
  • 1-year readmission rates were 9.9% for NOWS infants vs. 6.2% for non-NOWS infants.
  • Infants with NOWS had a 1.76 adjusted hazard ratio for readmission, with longer, costlier stays and higher ICU/ventilation needs.

Conclusions:

  • Infants diagnosed with NOWS exhibit a significantly higher likelihood of readmission within their first year of life.
  • Respiratory infections were the primary reason for readmission in NOWS infants.
  • Further research should focus on interventions to prevent NOWS readmissions and support affected families.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
56
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
55
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
542
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44